News | May 17, 2007

Genaera Corp. Begins Dosing in Phase 1 Trial of Obesity Compound Trodusquemine

May 18, 2007 — Genaera Corp. announced that dosing of subjects has begun in study MSI-1436C-101, the Phase 1, first-in-man study of trodusquemine, its novel antiobesity compound. MSI-1436 works centrally and peripherally to regulate insulin and leptin receptor signaling through inhibition of its novel target enzyme PTP-1B.

This randomized, vehicle-controlled study, being conducted at a leading obesity clinical research center in Kansas City, MO, is enrolling healthy overweight and obese volunteers to evaluate the safety, tolerability and pharmacokinetics of ascending single doses of intravenously administered MSI- 1436. This ascending single-dose protocol will initially enroll approximately 35 subjects and is expected to be completed in the second half of 2007.

"We are very pleased that we have met this clinical milestone and can begin to collect human data on this promising compound," said Jack Armstrong, president and chief executive officer of Genaera. "What we learn in this first stage of clinical testing will help us understand how MSI-1436 performs in the human body and guide the determination of an optimal therapeutic dose for the larger efficacy trials which follow. The efficiency and quality of this work will be important benchmarks for Genaera moving forward."

Related Content

Ingenia Ambition X 1.5T MR. This innovation is the latest advance in the Ingenia MRI portfolio, which comprises fully-digital MRI systems, healthcare informatics and a range of maintenance and life cycle services for integrated solutions that empower a faster, smarter, and simpler path to enabling a confident diagnosis
News | Magnetic Resonance Imaging (MRI) | September 14, 2018
Philips, a global leader in health technology, launched the Ingenia Ambition X 1.5T MR.
Videos | Radiation Therapy | September 07, 2018
A discussion with Ehsan Samei, Ph.D., DABR, FAAPM, FSPIE, director of the Duke University Clinical Imaging Physics Gr
Videos | Radiomics | August 09, 2018
A discussion with Martin Vallieres, Ph.D., post-doctoral fellow at McGill University, Montreal, Canada.
Gary D. Luker Named Editor of Radiology: Imaging Cancer

Image courtesy of University of Michigan Medical School

News | Oncology Diagnostics | August 06, 2018
The Board of Directors of the Radiological Society of North America (RSNA) announced that Gary D. Luker, M.D., will...
Videos | Digital Radiography (DR) | August 03, 2018
Sheila Sferrella, president of Regents Health Resources and Bill Finerfrock, president of Capitol Associates, discuss
Videos | AAPM | August 03, 2018
Ehsan Samei, Ph.D., DABR, FAAPM, FSPIE, director of the Duke Un...
New Regulatory Approvals Driving Research and Development Dollars in Medical Imaging Artificial Intelligence
News | Artificial Intelligence | August 01, 2018
Medical imaging has become the bellwether for the application of artificial intelligence (AI) technologies, especially...
Videos | Artificial Intelligence | August 01, 2018
A discussion with Steve Jiang, Ph.D., director of the medical...
Sectra radiation dose monitoring software can help manage radiation dose from multiple medical imaging modalities.
News | Radiation Dose Management | July 25, 2018
July 25, 2018 – Sectra will install its cloud-based,...
Magseed magnetic marker
Technology | Tumor Tracking Systems | July 20, 2018
Endomag, the surgical guidance company, received 510(k) clearance from the U.S.